Samsara BioCapital’s Kalaris Therapeutics KLRS Stock Holding History

Samsara BioCapital’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.4M	Sell	12,881,175 -66,906	-0.5%	-$348K	4.31%	7
2026 Q1	$74.7M	Hold	12,948,081	–	–	7.26%	5
2025 Q4	$109M	Buy	12,948,081 +1,500,000	+13%	+$9.59M	11.27%	3
2025 Q3	$66.2M	Hold	11,448,081	–	–	8.64%	3
2025 Q2	$30.6M	Hold	11,448,081	–	–	6.25%	4
2025 Q1	$91.9M	Buy	11,448,081 +11,444,501	+319,679%	+$112M	16.39%	2
2024 Q4	$34.6K	Hold	3,580	–	–	﹤0.01%	41
2024 Q3	$66.6K	Hold	3,580	–	–	0.01%	40
2024 Q2	$59.6K	Hold	3,580	–	–	0.01%	38
2024 Q1	$62.2K	Hold	3,580	–	–	0.01%	37
2023 Q4	$56K	Hold	3,580	–	–	0.01%	39
2023 Q3	$177K	Hold	3,580	–	–	0.05%	38
2023 Q2	$280K	Hold	3,580	–	–	0.05%	41
2023 Q1	$324K	Hold	3,580	–	–	0.07%	45
2022 Q4	$422K	Hold	3,580	–	–	0.09%	44
2022 Q3	$650K	Hold	3,580	–	–	0.15%	44
2022 Q2	$321K	Hold	3,580	–	–	0.09%	51
2022 Q1	$556K	Hold	3,580	–	–	0.14%	54
2021 Q4	$1.06M	Hold	3,580	–	–	0.21%	42
2021 Q3	$2.06M	Hold	3,580	–	–	0.32%	39
2021 Q2	$1.63M	Hold	3,580	–	–	0.2%	46
2021 Q1	$1.93M	Hold	3,580	–	–	0.36%	40
2020 Q4	$3.17M	Sell	3,580 -379	-10%	-$292K	0.32%	31
2020 Q3	$2.5M	Buy	+3,959	New	+$2.7M	0.7%	24

Other funds holding KLRS

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Samsara BioCapital's KLRS Position: Q2 2026 in Review

Samsara BioCapital reduced its Kalaris Therapeutics (KLRS) stake by 0.52% in Q2 2026, selling an estimated $348K and leaving 12,881,175 shares worth $52.4M. The position accounts for 4.31% of the portfolio, ranked #7.

Samsara BioCapital first reported a position in KLRS in Q3 2020 and has held it in 24 quarters since. The position peaked at $109M in Q4 2025. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

Samsara BioCapital held 12,881,175 shares of Kalaris Therapeutics worth $52.4M as of Q2 2026.
Samsara BioCapital sold 66,906 Kalaris Therapeutics shares in Q2 2026, an estimated $348K.
Kalaris Therapeutics made up 4.31% of Samsara BioCapital's portfolio in Q2 2026, its #7 holding.
Samsara BioCapital first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 24 quarters since.
Samsara BioCapital's Kalaris Therapeutics position peaked at $109M in Q4 2025.
57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Samsara BioCapital's 13F filing for Q2 2026, filed 14 Aug 2026.